Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/12/2021 (updated 4/10/2024)
64,000 people died from an overdose in the U.S. in 2016. Fentanyl-related deaths are up 540% in the last 3 years. In 2016 72% of the 1,374 fatal overdoses in NYC involved heroin and/or fentanyl
Posted 3/2/2021 (updated 4/4/2024)
All materials and resources have been translated to Spanish.
Posted 1/27/2021 (updated 4/4/2024)
The current study examined the accuracy of sensory discernment strategies by measuring study participants’ descriptions of the last opioid injected and checked with a fentanyl test strip (FTS) by that test's positive/negative result. The primary objective was to determine associations between FTS results and descriptions of the illi it opioid's physical appearance and physiological effects.
Posted 7/7/2021 (updated 4/2/2024)
In 2015, 33,091 persons in the United States died from an opioid-related drug overdose.The epidemic of opioid overdose deaths has led to expanding the use of naloxone in community settings by non–medically trained bystanders who are often people who use drugs (PWUD). Since 2013, illicitly manufactured fentanyl (IMF), fentanyl analogs, and other synthetic opioids have played an increasing role in overdose deaths in the United States. Illicitly manufactured fentanyl (IMF) prevalence has increased. However, there is uncertainty about naloxone dose(s) used by nonmedical bystanders to reverse opioid overdoses in the context of increasing IMF.
Posted 9/14/2022 (updated 3/27/2024)
The Reagan-Udall Foundation for the FDA (FDA Foundation), in partnership with several operating divisions within the Department of Health and Human Services (HHS), convened two roundtable meetings to understand the perspectives of the harm reduction community, clinicians, and researchers about using fentanyl drug checking and screening as harm reduction and clinical strategies.
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).